Literature DB >> 17133778

The effect of fexofenadine on pruritus in a mouse model (HR-ADf) of atopic dermatitis.

H Akamatsu1, M Makiura, N Yamamoto, A Yagami, Y Shimizu, K Matsunaga.   

Abstract

Fexofenadine, a histamine H1-receptor antagonist, is approved for the treatment of pruritus associated with atopic dermatitis. The effects of fexofenadine on scratching behaviour, and plasma levels of histamine and eotaxin were assessed in a new model of atopic dermatitis. Mice fed a diet low in Mg2+ and Zn2+ (special diet S) were compared with mice on a normal diet (N) or diet S plus fexofenadine HCl for weeks 0-10 (S + F(0-10)), 0-5 (S + F(0-5)) or 6 - 10 (S + F(6-10)) (seven mice per group). Compared with group N, group S mice showed significantly greater scratching frequency, and plasma histamine and eotaxin concentrations; these three variables were significantly lower in group S + F(0-10) than in group S. Scratching frequency increased when fexofenadine was discontinued. Fexofenadine significantly reduced mast cell and eosinophil numbers. Histamine may be important in the pathological changes seen in this model of atopic dermatitis, suggesting that it might aid future development of antihistamines for the treatment of atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17133778     DOI: 10.1177/147323000603400506

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

1.  Commentary on ''dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3β activation''.

Authors:  Torsten Zuberbier; Margitta Worm
Journal:  J Invest Dermatol       Date:  2014-02       Impact factor: 8.551

2.  Tonic inhibition of TRPV3 by Mg2+ in mouse epidermal keratinocytes.

Authors:  Jialie Luo; Randi Stewart; Rebecca Berdeaux; Hongzhen Hu
Journal:  J Invest Dermatol       Date:  2012-05-24       Impact factor: 8.551

3.  Expression and function of histamine and its receptors in atopic dermatitis.

Authors:  M Albrecht; A M Dittrich
Journal:  Mol Cell Pediatr       Date:  2015-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.